MMSI Merit Medical Systems Inc.

Merit Medical Launches basixSKY™ Inflation Device

Merit Medical Launches basixSKY™ Inflation Device

Versatile analog device offers fast inflation and ease of use, streamlining patient care

SOUTH JORDAN, Utah, May 21, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced the US commercial release of the basixSKY Inflation Device.

BasixSKY is the latest addition to Merit’s comprehensive inflation device portfolio, which includes both digital and analog devices. The basixSKY is available as a standalone solution and in kits with Merit Angioplasty Packs, configured to offer complementing AccessPLUS™, Honor®, and PhD™ hemostasis valves.

Designed with ease of use in mind, the new device is simple and highly responsive, creating an efficient approach to inflation. Rotational torque and handle revolutions to reach pressure are minimized, and a comfort-grip feature enables one-handed preparation.

Learn more about the basixSKY Inflation Device.

Endovascular interventions, such as balloon angioplasty and stent placement procedures used to widen narrowed or blocked coronary and peripheral arteries, utilize an inflation device. These are minimally invasive techniques that can restore blood flow through diseased vessels and minimize damage to surrounding tissue. In 2024, it is estimated that 1.79 million coronary balloon and stent placement procedures will be performed in the United States.1

“We are pleased to broaden our portfolio of inflation devices,” said Fred P. Lampropoulos, Merit’s Chairman and Chief Executive Officer. “With high-quality digital and analog solutions and custom kit options, we remain a leader in the inflation device market. We’re proud of that. We look forward to continuing to serve our healthcare partners, helping them to provide the best patient care.”

ABOUT MERIT MEDICAL Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling more than 700 individuals. Merit employs approximately 7,000 people worldwide. 

TRADEMARKS Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc., its subsidiaries, or its licensors.

CONTACTS 

PR/Media Inquiries 

Sarah Comstock 

Merit Medical 

  

INVESTOR INQUIRIES 

Mike Piccinino, CFA, IRC 

Westwicke - ICR 

 

1. Clarivate DRG, Market Insights ǀ Interventional Cardiology Devices ǀ United States ǀ 2023, December 29, 2022 (Clarivate, 2022).



EN
21/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Merit Medical Systems Inc.

Merit Medical Systems Inc: 2 directors

Two Directors at Merit Medical Systems Inc sold after exercising options/sold 10,000 shares at between 105.000USD and 105.310USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trade...

 PRESS RELEASE

Merit Medical Reports Fourth Quarter and Full Year 2024 Results and Is...

Merit Medical Reports Fourth Quarter and Full Year 2024 Results and Issues Fiscal Year 2025 Guidance Fourth Quarter Highlights† Reported revenue of $355.2 million, up 9.4%Constant currency revenue* and constant currency revenue, organic* up 10.1% and up 6.1%, respectivelyGAAP operating margin of 10.3%, compared to 10.4% in prior year periodNon-GAAP operating margin* of 19.6%, compared to 16.6% in prior year periodGAAP EPS $0.46, down 2.6%,Non-GAAP EPS* $0.93, up 25.8%, andFree cash flow* generation of $65.3 million, up 18.4% Fiscal Year 2024 Highlights† Reported revenue...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

S&P 500 Holding Above Prior Breakout Level Yet Again As discussed throughout the first half of January, we continue to believe that tariffs will mostly be used as a negotiation tactic, and much like Trump's prior presidency, will be much less impactful than feared. We reiterated this in yesterday's pre-market ETF Pathfinder, also noting "we anticipate the Canada/Mexico tariffs to be resolved relatively quickly, and therefore we view the latest pullback as a buying opportunity." Sure enough, bot...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

S&P 500 Testing Prior Breakout Level DeepSeek appears to have turned the chatbot market upside-down, putting pressure on AI-linked stocks. While the dust has yet to settle, the good news is that the selloff has been largely contained to these AI-linked stocks. The rest of the market did not seem to care; the equal-weighted S&P 500 was roughly flat yesterday. Additionally, market dynamics remain healthy, with Treasury yields, the U.S. dollar (DXY), and WTI crude oil continuing to move lower, and...

 PRESS RELEASE

Merit Medical Announces Preliminary Unaudited Revenue for the Year End...

Merit Medical Announces Preliminary Unaudited Revenue for the Year Ended December 31, 2024 and Plans to Announce Fourth Quarter and Year End 2024 Results and Issue Fiscal Year 2025 Guidance on February 25, 2025 2024 preliminary unaudited revenue in the range of approximately $1.355 billion - $1.357 billion, up approximately 7.7% - 7.9% year-over-year2024 preliminary constant currency revenue* increased in the range of approximately 8.4% - 8.6% year over year2024 financial results and 2025 guidance to be released February 25, 2025 * Constant currency revenue is a non-GAAP financial measure....

ResearchPool Subscriptions

Get the most out of your insights

Get in touch